The first personalised drug for prostate cancer is set to revolutionise treatment and extend the lives of thousands of men. The drug (olaparib) is currently licensed to treat ovarian cancer could be a successful treatment for men diagnosed with advanced prostate cancer. Currently in clinical trials, the pill is taken on a daily basis and uses the patient’s genetic make-up to target the tumour’s defences is said to work in 80 percent of men with certain genes.